Print Page  Close Window


SEC Filings

10-Q
OREXIGEN THERAPEUTICS, INC. filed this Form 10-Q on 05/12/2017
Entire Document
 

 

Orexigen Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2017

 

 

2016

 

Revenues:

 

 

 

 

 

 

 

 

Net product sales

 

$

19,041

 

 

$

 

Collaborative agreement

 

 

104

 

 

 

2,391

 

Royalties

 

 

 

 

 

2,642

 

Total revenues

 

 

19,145

 

 

 

5,033

 

Cost of product sales

 

 

6,187

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

8,173

 

 

 

11,801

 

Selling, general and administrative

 

 

55,247

 

 

 

16,551

 

Amortization expense of intangible assets

 

 

1,984

 

 

 

 

Change in fair value of contingent consideration

 

 

1,400

 

 

 

 

Total operating expenses

 

 

66,804

 

 

 

28,352

 

Loss from operations

 

 

(53,846

)

 

 

(23,319

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

 

147

 

 

 

123

 

Interest expense

 

 

(1,173

)

 

 

(1,936

)

Change in fair value of financial instruments

 

 

(28,006

)

 

 

 

Gain on extinguishment of debt

 

 

12,316

 

 

 

 

Foreign currency gain, net

 

 

1,475

 

 

 

2,784

 

Total other income (expense)

 

 

(15,241

)

 

 

971

 

Net loss

 

$

(69,087

)

 

$

(22,348

)

Net loss per share - basic and diluted

 

$

(4.67

)

 

$

(1.54

)

Shares used in computing basic and diluted net loss per share

 

 

14,806

 

 

 

14,556

 

 

See accompanying notes.

 

 

4